Correction to: Leukemia (2009) 23, 1329–1336; doi:10.1038/leukemia.2009.77; published online 16 April 2009
Since the publication of this paper, the authors have noticed an error in Figure 1. The correct figure is shown here.
(a) The levels of CD20, CD22, CD55 and CD59 antigens on Daudi and Raji cells were analyzed by flow cytometry after exposure to a medium with or without CMC-544. The horizontal lines show the fluorescence intensity, and the vertical lines show the levels of CD20, CD22, CD55 or CD59. White and black histograms show the data obtained after cells were incubated with G5/44 or CMC-544, respectively. The levels of CD22 and CD55 decreased 12–24 h after CMC-544 exposure, whereas those of CD20 increased. The levels of CD59 did not change significantly. (b) Results are shown from four representative patients with BCM that contained a sufficient number of cells for analysis. The same results were obtained for the remaining samples.
The authors apologize for this error.
Additional information
The online version of the original article can be found at 10.1038/leu.2009.77
Rights and permissions
About this article
Cite this article
Takeshita, A., Yamakage, N., Shinjo, K. et al. Erratum: CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. Leukemia 23, 1372 (2009). https://doi.org/10.1038/leu.2009.115
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2009.115
